Literature DB >> 16688261

Combined confocal/en face T-scan-based ultrahigh-resolution optical coherence tomography in vivo retinal imaging.

Radu G Cucu1, Adrian Gh Podoleanu, John A Rogers, Justin Pedro, Richard B Rosen.   

Abstract

Combined confocal scanning ophthalmoscopy/en face T-scan-based ultrahigh-resolution optical coherence tomography (OCT) of the human retina in vivo is reported for the first time to our knowledge. The system uses a superluminescent diode-based broadband source, which gives an axial resolution of 3.2 microm in the retina. We demonstrate acquisition of T-scan-based OCT B-scan and simultaneous confocal/C-scan images of the human retina of large lateral size (covering a field of up to 20 degrees ) at a frame rate of 2Hz.

Entities:  

Mesh:

Year:  2006        PMID: 16688261     DOI: 10.1364/ol.31.001684

Source DB:  PubMed          Journal:  Opt Lett        ISSN: 0146-9592            Impact factor:   3.776


  10 in total

Review 1.  Optical coherence tomography: history, current status, and laboratory work.

Authors:  Michelle L Gabriele; Gadi Wollstein; Hiroshi Ishikawa; Larry Kagemann; Juan Xu; Lindsey S Folio; Joel S Schuman
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-04-14       Impact factor: 4.799

2.  Ultrahigh-resolution optical coherence tomography/angiography with an economic and compact supercontinuum laser.

Authors:  Tai-Ang Wang; Ming-Che Chan; Hsiang-Chieh Lee; Cheng-Yu Lee; Meng-Tsan Tsai
Journal:  Biomed Opt Express       Date:  2019-10-11       Impact factor: 3.732

Review 3.  Three dimensional optical coherence tomography imaging: advantages and advances.

Authors:  Michelle L Gabriele; Gadi Wollstein; Hiroshi Ishikawa; Juan Xu; Jongsick Kim; Larry Kagemann; Lindsey S Folio; Joel S Schuman
Journal:  Prog Retin Eye Res       Date:  2010-06-11       Impact factor: 21.198

4.  "En face" OCT imaging of the IS/OS junction line in type 2 idiopathic macular telangiectasia.

Authors:  Ferenc B Sallo; Tunde Peto; Catherine Egan; Ute E K Wolf-Schnurrbusch; Traci E Clemons; Mark C Gillies; Daniel Pauleikhoff; Gary S Rubin; Emily Y Chew; Alan C Bird
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-09-14       Impact factor: 4.799

5.  Human chorioretinal layer thicknesses measured in macula-wide, high-resolution histologic sections.

Authors:  Christine A Curcio; Jeffrey D Messinger; Kenneth R Sloan; Arnab Mitra; Gerald McGwin; Richard F Spaide
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-06-06       Impact factor: 4.799

6.  Three-dimensional optical coherence tomography (3D-OCT) image enhancement with segmentation-free contour modeling C-mode.

Authors:  Hiroshi Ishikawa; Jongsick Kim; Thomas R Friberg; Gadi Wollstein; Larry Kagemann; Michelle L Gabriele; Kelly A Townsend; Kyung R Sung; Jay S Duker; James G Fujimoto; Joel S Schuman
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-10-24       Impact factor: 4.799

Review 7.  Optical coherence tomography.

Authors:  A Gh Podoleanu
Journal:  J Microsc       Date:  2012-06-18       Impact factor: 1.758

8.  Enface Thickness Mapping and Reflectance Imaging of Retinal Layers in Diabetic Retinopathy.

Authors:  Andrew W Francis; Justin Wanek; Jennifer I Lim; Mahnaz Shahidi
Journal:  PLoS One       Date:  2015-12-23       Impact factor: 3.240

9.  Alterations in Retinal Layer Thickness and Reflectance at Different Stages of Diabetic Retinopathy by En Face Optical Coherence Tomography.

Authors:  Justin Wanek; Norman P Blair; Felix Y Chau; Jennifer I Lim; Yannek I Leiderman; Mahnaz Shahidi
Journal:  Invest Ophthalmol Vis Sci       Date:  2016-07-01       Impact factor: 4.799

10.  In vivo imaging of the human eye using a 2-photon-excited fluorescence scanning laser ophthalmoscope.

Authors:  Jakub Boguslawski; Grazyna Palczewska; Slawomir Tomczewski; Jadwiga Milkiewicz; Piotr Kasprzycki; Dorota Stachowiak; Katarzyna Komar; Marcin J Marzejon; Bartosz L Sikorski; Arkadiusz Hudzikowski; Aleksander Głuszek; Zbigniew Łaszczych; Karol Karnowski; Grzegorz Soboń; Krzysztof Palczewski; Maciej Wojtkowski
Journal:  J Clin Invest       Date:  2022-01-18       Impact factor: 14.808

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.